杭州浙大迪迅生物基因工程有限公司Release date：2018-11-13
Clinical Reviews in Allergy & Immunology
DOI: org/10.1007/s12016-017-8650-3
Abstract:
The food allergy epidemic of recent years has led to the search for safe and effective methods of immunotherapy for foods. Studies of epicutaneous immunotherapy (EPIT) in mice have shown promising safety and efficacy data. Murine models have also identified probable mechanisms for the development of tolerance to food allergens, including the induction of regulatory T cells. Clinical data is lacking, but relatively small and early studies among peanut and cow’s milk allergic subjects suggest that EPIT has an excellent safety profile,particularly compared to other methods of specific allergen immunotherapy. Efficacy data are also promising for peanut allergy, among younger patients (ages 4–11 years of age),suggesting that a majority of young patients will experience an increase in reaction threshold with therapy. The goal of this therapy is the protection from accidental exposures to a known food allergen. Additional clinical data is needed to prove efficacy and further demonstrate the safety profile of EPIT for food allergy, prior to approval by the Food and Drug Administration.
First Author:
Bruce J. Lanser
Correspondence:
National Jewish Health
All Authors:
Bruce J. Lanser, Donald Y. M. Leung
[IF:6.442]
The Current State of Epicutaneous Immunotherapy for Food Allergy: a Comprehensive ReviewDOI: org/10.1007/s12016-017-8650-3
Abstract:
The food allergy epidemic of recent years has led to the search for safe and effective methods of immunotherapy for foods. Studies of epicutaneous immunotherapy (EPIT) in mice have shown promising safety and efficacy data. Murine models have also identified probable mechanisms for the development of tolerance to food allergens, including the induction of regulatory T cells. Clinical data is lacking, but relatively small and early studies among peanut and cow’s milk allergic subjects suggest that EPIT has an excellent safety profile,particularly compared to other methods of specific allergen immunotherapy. Efficacy data are also promising for peanut allergy, among younger patients (ages 4–11 years of age),suggesting that a majority of young patients will experience an increase in reaction threshold with therapy. The goal of this therapy is the protection from accidental exposures to a known food allergen. Additional clinical data is needed to prove efficacy and further demonstrate the safety profile of EPIT for food allergy, prior to approval by the Food and Drug Administration.
First Author:
Bruce J. Lanser
Correspondence:
National Jewish Health
All Authors:
Bruce J. Lanser, Donald Y. M. Leung
2018-10-25 Review
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd. Copyright HZKC Technical support 浙ICP备14005341号 （浙）-非经营性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist. Tel: 0571-87968248-805 Website:www.zdbiogene.com
COPYRIGHT©2003-2024 www.zdbiogene.com CORPORATION. ALL RIGHTS RESERVED
Official WeChat